p16(MTS-1/CDKN2/INK4a) in cancer progression

被引:396
|
作者
Rocco, JW
Sidransky, D
机构
[1] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA
[3] Johns Hopkins Univ Hosp, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21202 USA
关键词
D O I
10.1006/excr.2000.5149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since its discovery as an inhibitor of cyclin-dependent kinases 4 and 6, the tumor suppressor pie has continued to gain widespread importance in cancer. The high frequency of deletions of p16 in tumor cell lines first suggested an important role for p16 in carcinogenesis. This initial genetic evidence was subsequently strengthened by numerous studies documenting p16 inactivation in kindreds with familial melanoma. Moreover, a high frequency of p16 gene alterations was found in primary tumors, while recent studies have identified p16 promoter methylation as a major mechanism of tumor-suppressor-gene silencing. Additional insight into pie's role in cancer has come from the genetic analysis of precancerous lesions and various tissue culture models. It is now believed that loss of pie is an early and often critical event in tumor progression. Consequently, pie is a major tumor-suppressor gene whose frequent loss occurs early in many human cancers. (C) 2001 Academic Press.
引用
收藏
页码:42 / 55
页数:14
相关论文
共 50 条
  • [1] Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma
    Merbs, SL
    Sidransky, D
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (03) : 779 - 783
  • [2] Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer
    Benedict, WF
    Lerner, SP
    Zhou, J
    Shen, XH
    Tokunaga, H
    Czerniak, B
    ONCOGENE, 1999, 18 (05) : 1197 - 1203
  • [3] Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer
    William F Benedict
    Seth P Lerner
    Jain Zhou
    Xiaohua Shen
    Hideo Tokunaga
    Bogdan Czerniak
    Oncogene, 1999, 18 : 1197 - 1203
  • [4] p16(INK4A)/MTS1/CDKN2 - The melanoma gene? [p16(INK4A)/MTS1/CDKN2 das'melanomgen'? Stand der forschung und ausblick]
    Bogenrieder T.
    Landthaler M.
    Stolz W.
    Der Hautarzt, 1998, 49 (2): : 91 - 100
  • [5] DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours
    D M Woodcock
    M E Linsenmeyer
    J P Doherty
    W D Warren
    British Journal of Cancer, 1999, 79 : 251 - 256
  • [6] DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours
    Woodcock, DM
    Linsenmeyer, ME
    Doherty, JP
    Warren, WD
    BRITISH JOURNAL OF CANCER, 1999, 79 (02) : 251 - 256
  • [7] High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
    Reed, AL
    Califano, J
    Cairns, P
    Westra, WH
    Jones, RM
    Koch, W
    Ahrendt, S
    Eby, Y
    Sewell, D
    Nawroz, H
    Bartek, J
    Sidransky, D
    CANCER RESEARCH, 1996, 56 (16) : 3630 - 3633
  • [8] p16 MTS1 INK4A CDKN2与大肠癌
    黄文斌
    皖南医学院学报, 2001, (02) : 145 - 148
  • [9] CDKN2 (MTS1/p16(INK4A)) gene alterations in hematological malignancies
    Uchida, T
    Kinoshita, T
    Saito, H
    Hotta, T
    LEUKEMIA & LYMPHOMA, 1997, 24 (5-6) : 449 - 461
  • [10] Expression of CDK inhibitor p16(CDKN2/MTS1/INK4A) in human gastric carcinomas
    Yasui, W
    Yokozaki, H
    Kuniyasu, H
    Shimamoto, F
    Tahara, E
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 765 - 769